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Abstract:  The aim of study is to identify cisplatin-resistance associated biomarkers for  
non-small  cell  lung  cancers (NSCLC). We use  two-dimensional  electrophoresis (2-DE) 
combined with MALDI-TOF mass spectrometry to compare the proteome between lung 
cancer  cell  line  A549  and  its  cisplatin-resistant  subline  A549/DDP.  Nine  cisplatin  
resistance-related  proteins  were  identiﬁed,  and  DJ-1,  one  of  the  differently  expressed 
proteins, was selected for further validation and evaluation. Immunohistochemical results 
demonstrated that high expression level of DJ-1 was associated with cisplatin resistance 
and a predictor for poor prognosis in 67 locally advanced NSCLC patients. Furthermore, in 
vitro  results  showed  that  silencing  DJ-1  increased  the  proliferation  inhibitory  effect  of 
cisplatin  to  A549/DDP  cells.  In  conclusion,  DJ-1  might  play  an  important  role  in  the 
resistibility to cisplatin, and it could also act as a novel candidate biomarker for predicting 
the response of NSCLC patients to cisplatin-based chemotherapy. 
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1. Introduction 
Non-small cell lung cancer (NSCLC) accounts for most lung cancer cases. Currently, more than half 
of the patients diagnosed with NSCLC were in their advanced stages at diagnosis [1]. Cisplatin-based 
combination chemotherapies are used as standard treatment modalities for advanced NSCLC patients 
with  good  performance  status,  and  have  shown  a significant  improvement in  overall  survival  and 
quality of life. However, there are still some patients who exhibit drug resistance to cisplatin-based 
chemotherapy [2]. Therefore, identifying novel molecular markers related to cisplatin resistance would 
be helpful to further understand the exact mechanisms of chemo-resistance and make more individual 
chemotherapy strategies for NSCLC patients in the future.  
Previous  studies  have  identified  multiple  genetic  aberrations  that  might  contribute  to  cisplatin 
resistance  in  NSCLC  patients.  For  example,  Cobo  et  al.  [3]  reported  that  excision  repair  
cross-complementing 1 (ERCC1) mRNA expression confers selective resistance to cisplatin in NSCLC 
patients. Kim et al. [4] revealed that the BRCA1 haplotype is significantly associated with survival of 
NSCLC  patients  treated  with  platinum-based  chemotherapy.  Recently,  it  was  also  suggested  that 
transglutaminase 2 (TGM2) is a cisplatin resistance marker in non-small cell lung cancer [5]. With 
these drug resistance molecules, much effort is still needed to find novel biomarkers with potential 
utility in predicting the cisplatin resistance of NSCLC patients.  
In this present study, we first performed a proteomic approach to compare the differently regulated 
protein expression profiles between cisplatin-sensitive and -resistant lung cancer cell lines to screen 
candidate molecules related to cisplatin chemoresistance. Then we further confirmed that DJ-1, one of 
the differently regulated marker identified in proteomic analysis, is a novel cisplatin-resistant marker 
and  an  independent  prognostic  factor  for  locally  advanced  NSCLC  patients.  In  addition,  we  also 
validated an association between silencing DJ-1 with decreased cisplatin resistance in vitro.  
2. Results and Discussion 
2.1. Proteomic Analysis Identified DJ-1 Up-Regulated in Drug-Resistant A549/DDP Compared with 
Drug-Sensitive A549 Cells 
In this present study, we adopted a 2-DE analysis to quantitatively compare the protein profilings of 
NSCLC cell line A549 and its cisplatin-resistant subline A549/DDP. The differently expressed proteins 
with more than 2 fold changes between the two groups were selected to perform protein identification 
by MALDI-TOF. A total of 12 proteins were successfully identified, including 9 up-regulated proteins 
and 3 down-regulated proteins (Figure 1 and Table 1). The different expression of DJ-1 between A549 
and A549/DDP cells identified in proteomic study was further validated by Western blot analysis. As 
shown in Figure 2, A549/DDP cells had an increased expression level of DJ-1 compared to A549 cells, 
which is consistent with the finding of the proteomic analysis.  Int. J. Mol. Sci. 2011, 12                       
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Figure  1.  Representative  two-dimensional  electrophoresis  gels  (pI  3–10  NL,  18  cm) 
showing  that  9  protein  spots  up-regulated  in  A549/DDP  cells  (A)  and  3  protein  spots  
down-regulated compared with A549 cells (B) with arrows. 
 
Table 1. Differently expressed proteins between A549/DDP and A549 lung cancer cells in 
proteomic analysis. 
Spot 
Gene 
Symbol 
Protein Name 
Swiss-Prot 
Accession 
Fold *  Function 
1  VIM  Vimentin  P08670  3.76  structural constituent of cytoskeleton 
protein C-terminus binding 
2  ALDOA 
 
Fructose-bisphosphate  
aldolase A 
P04075 
 
−3.09  actin binding 
fructose binding 
fructose-bisphosphate aldolase activity 
identical protein binding 
tubulin binding 
3  HNRNPA2B1 
 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
P22626 
 
2.82  RNA binding 
nucleotide binding 
protein binding 
single-stranded telomeric DNA binding 
4  PGK1  Phosphoglycerate kinase 1  P00558  4.47  ATP binding 
phosphoglycerate kinase activity 
5  PRDX4  Peroxiredoxin 4  Q13162  8.11  thioredoxin peroxidase activity 
6  ANXA1 
 
Annexin A2  P04083  
 
5.93  calcium ion binding 
calcium-dependent phospholipid 
binding 
phospholipase A2 inhibitor activity 
protein binding, bridging 
receptor binding 
structural molecule activity 
7  PARK7  Protein DJ-1  Q99497  5.43  protein binding 
8  STMN1  Stathmin  P16949  3.49  signal transducer activity 
tubulin binding Int. J. Mol. Sci. 2011, 12                       
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Table 1. Cont. 
Spot 
Gene 
Symbol 
Protein Name 
Swiss-Prot 
Accession 
Fold *  Function 
9  PFN1 
 
Profilin-1  P07737  2.95  actin binding 
proline-rich region binding 
10  P07437 
 
Tubulin β chain  TUBB  
 
−5.31  GTP binding 
GTPase activity 
MHC class I protein binding 
11  P09972 
 
Fructose-bisphosphate  
aldolase C 
ALDOC 
 
−2.37  cytoskeletal protein binding 
fructose-bisphosphate aldolase activity 
12  P23528   Cofilin-1  CFL1  3.94  actin binding 
* A549/DDP vs. A549. 
Figure 2. Western-blot results showed that cisplatin-resistant A549/DDP cells (2) had a 
higher DJ-1 expression than A549 cell (1); siRNA transfected A549/DDP cells (4); had a 
decreased DJ-1 expression level than mock RNAi transfected A549/DDP cells (3). 
 
2.2.  DJ-1  Correlated  to  Cisplatin  Resistance  and  Predicted  Poor  Prognosis  in  Locally  Advanced 
NSCLC Patients 
To  evaluate  the  clinicopathological  significance  of  DJ-1  expression  in  NSCLC  patients,  we 
performed  an  immunohistochemical  analysis  on  67  locally  advanced  NSCLC  tumor  tissues.  DJ-1 
staining mainly located in the cytoplasm of cancer cells in NSCLC tissues (Figure 3). NSCLC cases 
were categorized into two groups based on the median H score: DJ-1-high group (n = 33, with an  
H score >28%) and DJ-1-low group (n = 34, with an H score ≤28%). As seen in Table 2, DJ-1-high 
group had a  significantly  higher frequency of cisplatin resistance than DJ-1-low group (57.6% vs. 
29.4%,  P  =  0.020).  No  significant  association  was  identified  between  DJ-1  expression  and  other 
clinicopathological characteristics.  
When the overall survival analysis of these patients was performed according to DJ-1 expression 
level  and  other  clinicopathological  characteristics,  cases  with  high  DJ-1  expression  level  had  a 
significantly  shorter  overall  survival  time  compared  with  DJ-1-low  subgroup  (Figure  4,  Table  3). 
Multivariate analysis was not performed because there was no other variable that might be considered 
in relation to overall time.  
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Figure  3.  Representative  images  of  immunostaining  of  DJ-1  in  primary  advanced  
non-small  cell  lung  cancer  tumors  with  DJ-1-low  expression  (A)  and  DJ-1-high 
expression (B) (200×  magnification).  
 
Table 2. Association of DJ-1 expression and clinicopathological characteristics in 67 locally 
advanced NSCLC patients. 
Characteristics 
Total 
(n = 67) 
DJ-1 Low 
Expression  
(n = 34) 
DJ-1 High 
Expression 
(n = 33) 
P Value 
Gender         
Male  48  26  22  0.373 
Female  19  8  11   
Age         
<60 year  29  17  12  0.260 
≥60 year  38  17  21   
Histology         
Squamous cell carcinoma  37  18  19  0.703 
Adenocarcinoma  30  16  14   
Pathologic stage         
IIIA  9  3  6  0.261 
IIIB  56  31  27   
Chemotherapy regimens         
NVB + DDP  29  17  12   
Taxol + DDP  23  10  13  0.521 
Gemzar + DDP  15  7  8   
Response to cisplatin-based 
chemotherapy 
       
Resistant  29  10  19  0.020 
Sensitive  38  24  14   
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Figure 4. Kaplan-Meier survival curves for overall survival (OS) of patients with locally 
advanced non-small cell lung cancer according to the expression level of DJ-1 (log rank 
test, P = 0.010).  
 
Table 3. Univariate analysis of overall survival with regard to clinicopathological characteristics. 
Characteristics  Univariate Analysis 
  HR (95% CI)  P 
Age  1.082 (0.641–1.825)  0.768 
Gender  1.434 (0.800–2.571)  0.226 
Histology  0.922 (0.547–1.556)  0.762 
Pathologic stage  0.691 (0.313–1.525)  0.360 
Chemotherapy regimens  0.609 (0.611–2.322)  0.609 
Response to cisplatin-based chemotherapy  0.688 (0.403–1.174)  0.170 
DJ-1 expression level  0.495 (0.291–0.843)  0.010 
2.3. Silencing of DJ-1 Partially Reversed Cisplatin Resistance in Drug-Resistant A549/DDP Cells 
To explore the relationship between DJ-1 expression and cisplatin-resistance in vitro, we performed 
siRNA treatment to down-regulate the DJ-1 expression level in A549/DDP cells (Figure 2), and then 
treated increasing concentrations of cisplatin. As seen in Figure 5, when the DJ-1 level was decreased 
in resistant lung cancer cells, the sensitivity to cisplatin increased. CKK-8 assay results showed that 
siRNA targeting transfected lung cancer cells had a higher inhibitory ratio than mock RNAi transfected 
controls after treatment with increasing concentrations of cisplatin.  Int. J. Mol. Sci. 2011, 12                       
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Figure 5. The relationship between silencing of DJ-1 and cisplatin resistance reversion in 
A549/DDP cells. After treated with increasing concentration of cisplatin, siRNA targeting 
DJ-1  transfected  A549/DDP  cells  had  a  higher  inhibition  rate  than  the  
mock-transfected and untransfected controls (P < 0.01, ANOVA test). 
 
2.4. Discussion 
Mining novel genes or proteins associated with cisplatin-resistance could not only be helpful in 
revealing  the  mechanisms  underlying  cisplatin  resistance,  but  also  be  of  potential  utility  in  the 
prediction of cisplatin resistance for NSCLC patients. The recently developed proteomic techniques 
provide an excellent tool in identifying novel cisplatin-resistance markers. For example, Gong et al. [6] 
identified  10  unique  proteins  differently  expressed  between  cisplatin-sensitive  and  -resistant 
ovarian cancer  cell  lines  by  2-DE  and  ESI-Q-TOF  MS/MS  analysis.  Li  et  al.  [7]  employed  the  
iTRAQ-LC-MSMS proteomic approach to compare the protein profilings between cisplatin-resistant 
COC1/DDP cell line and its parental COC1 cell line, and validated that PKM2 and HSPD1 could 
contribute considerably to the cisplatin resistance in ovarian cancer cells.  
In this study, we performed a 2-DE combined with MALDI-TOF analysis to identify differential 
proteins expression between cisplatin-sensitive (A549) and cisplatin-resistant (A549/DDP) lung cancer 
cell lines. We successfully identified 12 unique proteins with significantly altered expression levels. 
Based  on  their  functions,  these  proteins  are  mainly  involved  in  protein  binding  and  cytoskeletal 
proteins.  Some  of these proteins  such as  phosphoglycerate kinase 1 (PGK1), vimentin (VIM) and 
stathmin (STMN1), have been reported to be associated with chemotherapy resistance in previous 
proteomic studies, while our study also found several novel candidate resistance-associated proteins 
such as DJ-1, which will be valuable for further study of the mechanisms of cisplatin resistance and the 
clinical utility as a resistance marker.  
DJ-1 encodes a highly conserved protein belonging to the Thij/PfpI/DJ-1 superfamily [8]. With 
respect to cancer, increasing evidence suggests that DJ-1 plays an important role in tumor progression 
as a potent activator of the PI3K/Akt, mTOR and HIF1 pathway, and an inhibitor of p53-mediated 
apoptosis [8–10]. DJ-1 is frequently overexpressed in a large variety of solid tumors. Most recently, Int. J. Mol. Sci. 2011, 12                       
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Kim et al. [11] identified DJ-1 expression increased in 19 of 23 primary non-small cell lung carcinoma 
samples compared to paired nonneoplastic lung tissues. However, until now, no previous study has 
reported the association between DJ-1 expression with cisplatin resistance, and the clinicopathological 
significance of DJ-1 in NSCLC is also unknown. Therefore, we selected DJ-1 as a cisplatin-resistance 
tumor marker for further validation.  
Our Western blot results validated that DJ-1 expression increased in cisplatin-resistant lung cancer 
cells compared with its sensitive parent cell. In the following immunohistochemistry study, we found 
that DJ-1 expression level is positively associated with cisplatin resistance, and is also a prognostic 
factor for shorter survival time in NSCLC. Furthermore, in in vitro experiment, we also demonstrated 
that down-regulation of DJ-1 by RNAi in cisplatin-resistant lung cancer cells could sensitize them to 
cisplatin. These ﬁndings suggest that DJ-1 might participate in cisplatin resistance in NSCLC, and 
could serve as a potential biomarker for resistance prediction and prognosis.  
Considering that many previous studies have proved that PI3K/Akt, mTOR and HIF1 pathways 
have been confirmed to be involved in the cisplatin-resistance of cancer cells [12–15], we suggest that 
DJ-1 might mediate cisplatin resistance in NSCLC as an activator of these pathways, however, further 
works need to be done to clarify its definite function in chemotherapy resistance.  
3. Experimental Section 
3.1. Cell Lines and Patients 
Human lung adenocarcinoma cell line A549 cells were obtained from the American Type Culture 
Collection (ATCC), and its cisplatin-resistant subline A549/DDP was obtained from XiangYa Cell 
center,  Changsha,  China.  Cells  were  maintained  in  RPMI-1640  medium  supplemented  with  10%  
heat-inactivated fetal bovine serum, for A549/DDP cells, 2 µg/mL cisplatin was added. Three replicate 
tests were performed for all the in vitro analysis.  
A  total  of  67  locally  advanced  NSCLC  patients  including  37  squamous  cell  carcinomas  and 
30 adenocarcinomas undergoing resection or biopsy in Shandong University Medical College (Jinan, 
China) and Tongji Hospital (Shanghai, China) between February 2000 and July 2007 were included  
in  this  study.  All  the  patients  included  were  treated  with  at  least  three  cycles  of  post-operational 
cisplatin-based third-generation chemotherapy doublets including NP regimens (NVB and DDP), TP 
regimens  (Taxol  and  DDP),  and  GP  regimens  (Gemzar  and  DDP).  Cisplatin-based  chemotherapy 
responses were evaluated according to the WHO criteria, which classified the responses into complete 
response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Patients with 
CR and PR were defined as sensitive to cisplatin-based chemotherapy; the other patients with PR and 
SD  were  defined  as  resistant.  The  study  was  approved by the local  ethics  committees. All  tumor 
specimens  analyzed  were  collected  before  chemotherapy  with  informed  consent.  The  detailed 
clinicopathological characteristics of the subjects are listed in Table 2.  
3.2. Two-Dimensional Gel Electrophoresis (2-DE) and Mass Spectrometry Analysis 
The A549 cells and A549/DDP cells were harvested and lysed in a buffer containing 7 M urea, 2 M 
thiourea, 4% w/v, 40 mM DTT, 0.5% IPG buffer (pH 3–10, NL). The lysate was then subjected to Int. J. Mol. Sci. 2011, 12                       
 
 
3497 
centrifugation at 10,000 rpm for 10 min to remove cell debris. Bradford assay was used to determine 
the total protein concentration. 500 μg of protein samples diluted in lysis buffer were applied to 18 cm 
non-linear  IPG  strips  pH  3–10  (Bio-Rad).  IEF  were  performed  in  a  Protean  IEF  cell  apparatus  
(Bio-Rad). After the first dimension, the strips were balanced in an equilibration buffer (6 M urea, 
75 mM Tris-HCl pH 8.8, 29.3% glycerol, 2% SDS and 0.002% bromophenol blue) containing 1% DTT 
for 10 min, and then in the same equilibration buffer containing 2.5% iodoacetamide instead of DTT 
for an additional 10 min. The second dimension electrophoresis was carried out using Protean II XL 
cell  apparatus  (Bio-Rad).  The  protein  gels  were  visualized  by  Coomassie  Brilliant  Blue 
R350 (Amersham  Biosciences),  and  scanned  with  a  GS-800  Calibrated  Densitometer  (Bio-Rad)  at 
300 dpi resolution. Images were analyzed using PDQuest software (Bio-Rad). Differently expressed 
spots were excised from 2-DE gels and in-gel digested with modified trypsin (Promega). Extracted 
peptides were analyzed by a Voyager-DE STR MALDI-TOF mass spectrometer (Applied Biosystems). 
Database searching of MS data was performed using Mascot software (Matrix Science Ltd).  
3.3. Western-Blot 
About  30  μg  extracted  protein  samples  were  separated  by  12%  SDS-polyacrylamide  gel 
electrophoresis, and then nitrocellulose membrane transferring was conducted. The membrane was 
blocked  with  5%  defatted  milk  and  incubated  with  a  rabbit  polyclonal  antibody  against  human  
DJ-1  (Abcam)  and  β-actin  antibody  (Santa  Cruz  Biotech)  at  1:1000  dilutions  overnight  at  4  °C . 
Detection was performed using an ECL chemiluminescence reagent (Amersham).  
3.4. Immunohistochemistry 
Immunohistochemical  staining  was  performed  on  4  μm  of  formalin-fixed,  paraffin-embedded 
sections  of  67  NSCLC  tumor  tissues.  Briefly,  antigen  retrieval  was  performed  in  0.01  M  citrate 
buffer (pH 6.0); endogenous peroxidase activity was blocked with hydrogen peroxide for 5 min at 
room temperature. Then sections were incubated with the same antibody against human DJ-1 used in 
Western-blot analysis (1:200 dilution) at 4 ° C overnight. Visualization was performed using a DAKO 
EnVision system. Nonspecific rabbit IgG was used as a negative control.  
Expression of DJ-1 stains were scored based on the percentage of positive tumor cells and the 
intensity of staining (graded on a scale of 0–3:0, no staining; 1, weak; 2, moderate; 3, strong). A 
semiquantitative H-score was obtained by multiplying the density and intensity of staining. Cases were 
categorized into two groups based on the median value of all the H-scores in NSCLC specimens:  
DJ-1-high  (H-scores  more  than  median  value)  and  DJ-1-low  (H-scores  less  than  or  equal  to 
median value) [16].  
3.5. RNA Interference and Cisplatin Sensitivity Assay 
To  silence  DJ-1  expression,  a  small  interfering  RNA  (siRNA)  duplex  targeting  human  DJ-1  
(5'-GATTAAGGTCACCG-3') was introduced into 1 ×  10
6 A549/DDP cells using lipofectamine (Invitrogen) 
according to the manufacturer’s instruction as described previously. Cells were double-transfected at Int. J. Mol. Sci. 2011, 12                       
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72 h intervals and then were harvested for further analysis. Specific silencing of the targeted gene was 
validated by Western blot.  
After the transfection, 1 ×  10
4 A549/DDP cells were plated in 96-well plates and then were exposed 
to various concentrations of cisplatin (0.2–200 μg/mL) for 24 h. Following cisplatin treatment, the 
10 μL of Cell Counting Kit-8 solution was added to each well and the mixture was incubated at room 
temperature for 1h. After the incubation, the absorbance at 450 nm was determined. The cell inhibition 
ratio was calculated as a fraction of the untreated controls.  
3.6. Statistical Analysis 
The correlation between DJ-1 expression and the clinicopathological characteristics of NSCLC were 
analyzed using Fisher’s exact test. The inhibition rates among groups were analyzed by ANOVA test. 
The overall survival (OS) time was defined as the time from operation to cancer-caused death. The 
survival curves were estimated by the Kaplan-Meier method, and differences were compared by the 
log-rank test. Statistically significant prognostic factors identified in univariate analyses were selected 
to enter multivariable analyses using a Cox proportional hazards model. Statistical analyses were performed 
using SPSS 11.0 software for Windows. A p value less than 0.05 was set as statistically significant.  
4. Conclusions 
In conclusion, in this present study, using a proteomic approach, we identiﬁed and validated DJ-1 
being  a  novel  cisplatin-resistance  marker  and  a  prognostic  factor  for  advanced  NSCLC  patients. 
Furthermore, our in  vitro demonstrated that inhibition  of DJ-1 may overcome  cisplatin resistance, 
which suggesting DJ-1 might serve as a potential target for the reversal of drug resistance in NSCLC 
patients, and ultimately lead to improved clinical outcomes.  
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